These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 19355803)

  • 21. [Economic impact of overactive bladder symptoms in Japan].
    Inoue S; Kobayashi M; Sugaya K
    Nihon Hinyokika Gakkai Zasshi; 2008 Nov; 99(7):713-22. PubMed ID: 19068687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction.
    Irwin DE; Kopp ZS; Agatep B; Milsom I; Abrams P
    BJU Int; 2011 Oct; 108(7):1132-8. PubMed ID: 21231991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.
    Qin L; Luo X; Zou KH; Snedecor SJ
    J Med Econ; 2016; 19(3):229-35. PubMed ID: 26488196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
    Pelletier EM; Vats V; Clemens JQ
    Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Economic considerations in overactive bladder.
    Hu TW; Wagner TH
    Am J Manag Care; 2000 Jul; 6(11 Suppl):S591-8. PubMed ID: 11183902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Defining overactive bladder: epidemiology and burden of disease.
    Tubaro A
    Urology; 2004 Dec; 64(6 Suppl 1):2-6. PubMed ID: 15621220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.
    Birnbaum HG; Kessler RC; Lowe SW; Secnik K; Greenberg PE; Leong SA; Swensen AR
    Curr Med Res Opin; 2005 Feb; 21(2):195-206. PubMed ID: 15801990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overactive bladder syndrome among community-dwelling adults in Taiwan: prevalence, correlates, perception, and treatment seeking.
    Yu HJ; Liu CY; Lee KL; Lee WC; Chen TH
    Urol Int; 2006; 77(4):327-33. PubMed ID: 17135783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Burden of illness associated with lower urinary tract symptoms including overactive bladder/urinary incontinence.
    Kannan H; Radican L; Turpin RS; Bolge SC
    Urology; 2009 Jul; 74(1):34-8. PubMed ID: 19428076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and associated factors of overactive bladder in Korean children 5-13 years old: a nationwide multicenter study.
    Chung JM; Lee SD; Kang DI; Kwon DD; Kim KS; Kim SY; Kim HG; Moon du G; Park KH; Park YH; Pai KS; Suh HJ; Lee JW; Cho WY; Ha TS; Han SW;
    Urology; 2009 Jan; 73(1):63-7; discussion 68-9. PubMed ID: 18829077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study.
    Vaughan CP; Johnson TM; Ala-Lipasti MA; Cartwright R; Tammela TL; Taari K; Auvinen A; Tikkinen KA
    Eur Urol; 2011 Apr; 59(4):629-36. PubMed ID: 21306820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
    Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
    BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimated economic costs of overactive bladder in the United States.
    Hu TW; Wagner TH; Bentkover JD; LeBlanc K; Piancentini A; Stewart WF; Corey R; Zhou SZ; Hunt TL
    Urology; 2003 Jun; 61(6):1123-8. PubMed ID: 12809878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The wet patient: understanding patients with overactive bladder and incontinence.
    Serels S
    Curr Med Res Opin; 2004 Jun; 20(6):791-801. PubMed ID: 15200735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-related consequences of overactive bladder: an economic perspective.
    Hu TW; Wagner TH
    BJU Int; 2005 Sep; 96 Suppl 1():43-5. PubMed ID: 16086679
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The annual impact of seasonal influenza in the US: measuring disease burden and costs.
    Molinari NA; Ortega-Sanchez IR; Messonnier ML; Thompson WW; Wortley PM; Weintraub E; Bridges CB
    Vaccine; 2007 Jun; 25(27):5086-96. PubMed ID: 17544181
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Overactive bladder: prevalence and implications in Brazil.
    Teloken C; Caraver F; Weber FA; Teloken PE; Moraes JF; Sogari PR; Graziottin TM
    Eur Urol; 2006 Jun; 49(6):1087-92. PubMed ID: 16497431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost of clinically significant urinary storage symptoms for community dwelling adults in the UK.
    Turner DA; Shaw C; McGrother CW; Dallosso HM; Cooper NJ;
    BJU Int; 2004 Jun; 93(9):1246-52. PubMed ID: 15180616
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An epidemiological survey of overactive bladder symptoms in Japan.
    Homma Y; Yamaguchi O; Hayashi K;
    BJU Int; 2005 Dec; 96(9):1314-8. PubMed ID: 16287452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence of overactive bladder and incontinence in Canada.
    Corcos J; Schick E
    Can J Urol; 2004 Jun; 11(3):2278-84. PubMed ID: 15287994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.